9 August 2021 - Liminal BioSciences announced today that its subsidiary ProMetic Biotherapeutics has entered into a definitive agreement to sell its rare paediatric disease priority review voucher for USD105 million.

The priority review voucher was granted by the U.S. FDA with the approval of Ryplazim (plasminogen, human-tvmh) for treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia).

Read Liminal BioSciences press release